Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcipotriol Plus 5-FU Immunotherapy for SCC Prevention in Organ Transplant Candidates
NCT04329221Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of AKP01 in cutaneous squamous cell carcinoma (cSCC), actinic keratosis (AK), sponsored by Massachusetts General Hospital. Planned start Jan 2026; status: withdrawn.
02
Drugs
AKP01
03
Conditions
cutaneous squamous cell carcinoma (cSCC)actinic keratosis (AK)
Beyond the preview
Go deeper on NCT04329221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329221.